Navigation Links
Top Hepatitis C Treatments Equally Effective

Landmark assessment also finds treating early helps prevent liver failure

WEDNESDAY, July 22 (HealthDay News) -- A landmark hepatitis C virus study shows that the top two treatment options are equally effective and safe.

The long-awaited study, thought to be the largest of its kind, is important for the 180 million people worldwide -- 4 million in the United States -- who are infected with hepatitis C virus and at risk for liver scarring, organ failure and death.

Hepatitis C is America's leading cause of liver failure, liver cancer and liver transplantation. The disease is transmitted by contact with blood through sexual activities, drug use or personal care items.

The study of 3,070 adults at Johns Hopkins and 118 other U.S. medical centers showed that treating patients with either of the two standard antiviral therapies is safe and helps prevent liver damage.

The report appears online July 22 in the New England Journal of Medicine.

The drug therapies -- peginterferon alfa-2b plus ribavirin, or peginterferon alfa-2a plus ribavirin -- worked in 39.8 percent and 40.9 percent of patients, respectively. Commonly observed side effects included anemia, fatigue, headache, nausea, insomnia and depression.

The equality of the only two U.S. Food and Drug Administration-approved drug-treatment regimens for suppressing the virus surprised the researchers, according to a news release from Johns Hopkins.

"When considering treatments for hepatitis C infection, patients and their doctors now have solid evidence that they can weigh both antiviral therapies equally for effectiveness, safety and tolerability," Dr. Mark Sulkowski, medical director of the Johns Hopkins Center for Viral Hepatitis and the study's co-principal investigator, said in the news release.

While 10 percent to 13 percent of the study's participants quit the treatment because of side effects, Sulkowski said that was "within expectations for this type of therapy."

The researchers also found that the sooner patients get into treatment, the better.

"Treatment success is highly dependent on starting before liver cirrhosis has already set in, which can take from a year to decades," Sulkowski noted in the news release.

Evidence from the study also will help doctors learn more quickly whether the patient is responding to the drug therapy. This will allow patients to avoid side effects and the expense of taking unnecessary drugs.

The study was funded by the Schering-Plough Corp., the maker and provider of the study drugs ribavirin and peginterferon alfa-b.

More information

The U.S. Centers for Disease Control and Prevention has more information on hepatitis.

-- Dennis Thompson

SOURCE: Johns Hopkins University, news release, July 22, 2009

Copyright©2009 ScoutNews,LLC.
All rights reserved  

Related medicine news :

1. Mass. General-based research center will investigate why immune system fails to control hepatitis C
2. New Report Just Published: World Hepatitis C Virus And Therapeutics Market Report
3. Pharmasset Nominates PSI-938 as a New Nucleotide Analog Inhibitor of Hepatitis C for Preclinical Development
4. JNCI news brief: Hepatitis B virus mutations may predict risk of liver cancer
5. Hepatitis C Virus Market Will Expand Dramatically From $2 Billion in 2008 to Nearly $7.7 Billion in 2013
6. Good news for some hard-to-treat hepatitis C patients
7. Aethlon Medical Releases Shareholder Letter to Discuss the Treatment of Hepatitis-C Virus (HCV)
8. Pharmasset Initiates Phase 1b Multiple Ascending Dose Clinical Trial of PSI-7851 in Chronic Hepatitis C Patients
9. NEJM study points to new era in hepatitis C treatment
10. Resource for Those Living with Hepatitis C Announces Website Redesign
11. AUDIO from Medialink, Bayer Healthcare and Onyx Pharmaceuticals: Facts About Hepatitis
Post Your Comments:
Related Image:
Top Hepatitis C Treatments Equally Effective 
(Date:11/25/2015)... ... November 25, 2015 , ... “While riding the bus, I ... Bronx, N.Y. “I thought there had to be a convenient and comfortable way to ... The PROTECTOR enables disabled individuals to safely travel during cold or inclement weather. In ...
(Date:11/25/2015)... , ... November 25, 2015 , ... ... (PHA) announces the nation’s Periwinkle Pioneers, individuals and groups responsible for advancing care ... disease. The Periwinkle Pioneers, nominated by the public, will receive special recognition throughout ...
(Date:11/25/2015)... ... November 25, 2015 , ... ... philanthropic seniors, is resulting in a way for homeless people to have a ... have launched a new initiative whereby they are repurposing plastic bags into sleeping ...
(Date:11/25/2015)... ... November 25, 2015 , ... Since its launch in 2012, ... adult stem cell therapies to patients with chronic degenerative medical conditions. Now, the ... Registered Trademark (RTM). , Organizations are required to hold a registered trademark in ...
(Date:11/24/2015)... ... November 25, 2015 , ... Genesis Chiropractic Software ... software creates an agreement between the practice owner and the patient that automatically ... notification, and projections. Click here to learn more. , ...
Breaking Medicine News(10 mins):
(Date:11/24/2015)... FRANCISCO , Nov. 24, 2015  Thanks to ... Dignity Health St. Mary,s Medical Center,s Sister Diane Grassilli ... breast imaging capabilities in San Francisco ... an anonymous friend, stepped forward with a gift of ... for Breast Digital Mammography with Tomosynthesis and Whole Breast ...
(Date:11/24/2015)... Colo. , Nov. 24, 2015  Array ... that its Chief Executive Officer, Ron Squarer ... Healthcare Conference in New York.  The public is ... webcast on the Array BioPharma website.Event:Piper Jaffray Annual ... , Wednesday, December 2, 2015Time:1:30 p.m. Eastern Time ...
(Date:11/24/2015)... HOUSTON, TX and VANCOUVER, Nov. 24, 2015 /PRNewswire/ ... EPI; NASDAQ: EPIX ) announced today that the ... clinical study of EPI-506 as a treatment for metastatic ... States and Canada.  --> ... --> In the Phase 1/2 clinical trial, ...
Breaking Medicine Technology: